Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

£3m Dementia Consortium Launched

Published: Wednesday, December 11, 2013
Last Updated: Wednesday, December 11, 2013
Bookmark and Share
New Consortium aims to boost dementia drug discovery by uniting charity, academic and private sectors in search for new treatments.

As the UK hosts the first G8 summit on dementia research, a new £3 million Dementia Consortium bringing together research experts from the charitable, academic and private sectors has launched to expedite development of new drugs for dementia. The Dementia Consortium unites the charity Alzheimer’s Research UK with life science technology transfer experts MRC Technology and two pharmaceutical companies; Eisai and Lilly.

The Consortium will seek to end the long wait since the last dementia treatment by closing the gap between fundamental academic research and the pharmaceutical industry’s drug discovery programmes. The Dementia Consortium will provide funding, resources and expertise to both increase the number of, and capitalise upon, new drug targets emerging from across the academic sector that hold promise of bringing patient benefit.

The Dementia Consortium will fund leading academic dementia research experts from Alzheimer’s Research UK and MRC Technology’s networks in the UK and overseas to develop early findings into validated drug targets. Academic teams will work with MRC Technology’s world-leading Centre for Therapeutics Discovery to help confirm viable drug targets for further development.

Promising targets will be made available in the first instance to the Consortium’s pharmaceutical member companies Eisai and Lilly who are able to agree terms of collaboration with the academic partner and share data from any previous work on particular drug targets.

The Consortium has made £3m available (£2m from Alzheimer’s Research UK and £500k from both Eisai and Lilly) and a call will go out in the UK and internationally for academic teams to apply for funding to develop their targets. Applications will be submitted to the Consortium by April 2014, with projects underway mid-year. Pre-registration is now open at 

Dr Eric Karran, Director of Research at Alzheimer’s Research UK, the UK’s leading dementia research charity, said: “The G8 is an ideal platform to launch this important drug discovery collaboration as it exemplifies the new kind of partnership we need to produce breakthrough treatments. The Dementia Consortium draws on the strengths of the academic and industrial research sectors and unites them with a view to producing patient benefits more quickly. It will complement the work of our new Drug Discovery Institute, allowing us to both invest in dedicated drug discovery resource as well as supporting the ideas from across the dementia research sector as a whole. Over 35 million people live with dementia worldwide, a number set to increase as populations live ever longer. We must feed more promising drug targets into the development pipeline, and the Dementia Consortium will do just that.” 

Professor Justin Bryans, Director of Drug Discovery at MRC Technology added: “We are delighted that our Centre for Therapeutics Discovery will be able to use its proven drug discovery capabilities to validate promising dementia targets. This new consortium model leads the way by bringing together the very best charity, industry and academic expertise in precompetitive collaboration to accelerate much needed treatments towards patients. We hope to develop further consortia based on this model for other areas of unmet medical need.”

Dr Lynn Kramer, Chief Clinical Officer, Eisai Co. Ltd and President, Neuroscience & General Medicine PCU, Eisai Product Creation Systems, said: “Dementia is a condition that devastates families and is a significant unmet medical need due to current lack of effective treatments to prevent disease progression. Within the Dementia Consortium, we hope that our complementary expertise will combine to validate potential new drug targets that can be utilised to identify life changing therapeutics for dementia patients and their families. The Dementia Consortium has exciting implications for increasing the progression and expansion of dementia drug discovery research in the UK.”

Eli Lilly and Company’s Chief Scientific Officer for Neurodegeneration Dr Mike Hutton said: “Lilly is delighted to be part of this innovative collaboration, which we believe will help speed the development of new treatments for dementia by accessing the remarkable quality of UK academic research in this area. Lilly have been active in Alzheimer’s disease research for 25 years, and we believe it is through collaboration between industry, charities and academia that we will increase the number of potential drug targets that can be investigated and which could become the medicines of the future.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

MRC Technology Negotiates License with Bio-Techne for MRC’s GOPAL Protein Synthesis Technology
Technology enables production of ubiquitin reagents and other proteins for use in drug discovery.
Wednesday, August 27, 2014
Dementia Consortium Wins One Nucleus BioNewsRound Award
MRC Technology presented with award celebrating the most creative, significant and exciting news stories from One Nucleus member companies.
Friday, July 04, 2014
Scientific News
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Turning up the Tap on Microbes Leads to Better Protein Patenting
Mining millions of proteins could become faster and easier with a new technique that may also transform the enzyme-catalyst industry, according to University of California, Davis, researchers.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Novel Proteins Linked to Huntington's Disease
University of Florida Health researchers have made a new discovery about Huntington's disease, showing that the gene that causes the fatal disorder makes an unexpected "cocktail" of mutant proteins that accumulate in the brain.
Enzyme Critical to Maintaining Telomere Length Discovered
New method expected to speed understanding of short telomere diseases and cancer.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos